Why the study?
To assess the benefits and harms of PPIs versus H2RA or placebo for preventing upper gastrointestinal bleeding in adults receiving antithrombotic therapy.
Do proton-pump inhibitors prevent upper gastrointestinal bleeding compared to H2RA or placebo in adults receiving antithrombotic therapy?
Do proton-pump inhibitors prevent upper gastrointestinal bleeding compared to H2RA or placebo in adults receiving antithrombotic therapy?
This is a protocol for a Cochrane Review to evaluate the efficacy and safety of PPIs for preventing upper gastrointestinal bleeding in patients on antithrombotic therapy.
Answers are grounded in this paper and cite their sources.
Optimal UGIB prevention on antithrombotics remains undefined; protocol leaves open PPI versus H2RA evidence synthesis.
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of PPIs versus histamine‐2 receptor antagonists (H2RA) or placebo for the prevention of UGIB in adults receiving antithrombotic therapy for cardiovascular prevention, or prevention and treatment of thromboembolic disease.
No takes yet. Share an insight, caveat, or question.
Causada-Calo et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: